Retatrutide Phase 3 TRIUMPH Trials Show Continued Weight Loss Efficacy
Eli Lilly's triple incretin agonist Retatrutide (LY3437943) continues to demonstrate superior weight loss outcomes in ongoing Phase 3 TRIUMPH trials. Phase 2 data showed up to 24.2% body weight reduction over 48 weeks — the highest recorded for any peptide therapeutic to date.